Medtronic announces early data for the Intrepid transcatheter mitral valve replacement system using new transfemoral delivery system
Transfemoral access added into landmark APOLLO Pivotal Trial following IDE approval from FDA - Medtronic plc a global leader in healthcare technology, today presented early data for its self-expanding Intrepid ™ transcatheter mitral valve replacement system in patients with severe, symptomatic mitral valve regurgitation utilizing the transfemoral access route. Presented as Late-Breaking Clinical Science at the ...
Source: investingnews.com
